Benefits
Used in Major Cancer Trials
Selenium yeast was the form used in: NPC TRIAL (Nutritional Prevention of Cancer, Clark 1996) which initially suggested cancer prevention benefit; and SELECT TRIAL (Lippman 2009) which definitively showed NO cancer prevention benefit and possible T2DM risk signal. Provides historical/research context.
Diverse Selenoamino Acids
Selenium yeast contains selenomethionine (~70-90%) plus selenocysteine, selenocystathionine, methylselenocysteine, and small amounts of inorganic selenite — broader profile than pure selenomethionine. Theoretical advantage of yeast-derived nutritional matrix.
Food-Form Selenium
Marketed as 'food-form' selenium for those preferring whole-food approaches over isolated nutrients. Yeast-grown nutrients have somewhat better absorption profiles than synthetic forms in some cases.
Standardization in Branded Forms
SelenoExcell® (Cypress Systems) is the standardized selenium yeast used in SELECT and NPC trials — well-characterized selenium speciation. Generic selenium yeast products vary in standardization.
Selenium Deficiency Treatment
Effective for raising plasma selenium and selenoproteins in deficient populations. Comparable to selenomethionine for repletion.
Mechanism of action
Yeast Selenium Speciation
Saccharomyces cerevisiae grown in selenium-enriched media incorporates selenium into amino acids — converting methionine → selenomethionine via the methionine biosynthesis pathway. The resulting yeast contains ~70-90% selenomethionine plus minor selenoamino acids.
Broad Selenoprotein Support
Once digested and absorbed, selenium yeast components feed into selenoamino acid pool — supporting synthesis of all >25 selenoproteins (glutathione peroxidases, thioredoxin reductases, iodothyronine deiodinases, selenoprotein P, etc.).
Yeast Nutritional Matrix
Whole yeast also provides B vitamins, beta-glucans (immune-modulatory), nucleotides — possibly contributing to broader nutritional effects beyond selenium alone.
Slow Selenium Release
Selenium incorporated into yeast proteins is released gradually during digestion — different release kinetics than free selenomethionine or sodium selenite.
Clinical trials
Large RCT (n=35,533) of selenium yeast (200 µg/day selenomethionine equivalent) and/or vitamin E for prostate cancer prevention in healthy men. (Lippman et al. 2009, JAMA — and follow-up Klein 2011)
35,533 men.
PRIMARY ENDPOINT NEGATIVE: neither selenium yeast nor vitamin E reduced prostate cancer incidence. CRITICAL: vitamin E ALONE INCREASED prostate cancer risk (~17%); selenium showed possible T2DM RISK SIGNAL in subgroups. Definitive negative trial that reversed enthusiasm for selenium chemoprevention.
Earlier RCT (Clark 1996, n=1,312) of selenium yeast (200 µg/day) vs placebo for skin cancer prevention. Secondary analysis suggested reduced prostate cancer incidence.
1,312 patients with prior nonmelanoma skin cancer.
Initial findings suggested selenium yeast might reduce prostate cancer (secondary outcome). Generated enormous enthusiasm and motivated SELECT. SELECT subsequently failed to replicate. Demonstrates importance of confirmatory rigorous trials before clinical recommendation.
About this ingredient
Selenium yeast (high-selenium yeast) is Saccharomyces cerevisiae grown in selenium-enriched media — the yeast incorporates selenium into amino acids producing a 'food-form' selenium supplement. Composition: ~70-90% selenomethionine, plus selenocysteine, methylselenocysteine, selenocystathionine, small amounts of inorganic selenite. Standardized commercial selenium yeast (SelenoExcell® Cypress Systems) is the form used in SELECT and NPC trials.
RDA: 55 µg/day.
UL: 400 µg/day adults.
CRITICAL TRIAL CONTEXT: (1) NPC TRIAL (Clark 1996, n=1,312) — secondary analysis suggested cancer prevention benefit; (2) SELECT TRIAL (Lippman 2009, n=35,533) — DEFINITIVELY NEGATIVE for prostate cancer prevention; vitamin E component INCREASED prostate cancer risk by 17%; selenium subgroup showed T2DM risk signal. The selenium chemoprevention paradigm of the 1990s was substantially reversed by SELECT.
EVIDENCE-BASED USES: (1) Selenium repletion in deficient populations; (2) Selenium-deficient soil regions; (3) HIV adjunct (modest immune support); (4) Hashimoto's adjunct (limited evidence with selenium yeast specifically; selenomethionine evidence stronger).
CRITICAL CAUTIONS: (1) SELENIUM TOXICITY (SELENOSIS) — chronic >800 µg/day; documented in 2008 Total Body Formula contamination; (2) SELECT — selenium yeast did NOT prevent cancer; possible T2DM risk signal in selenium-replete populations; (3) MOST ADULTS in selenium-adequate regions DO NOT NEED supplementation; (4) BRAZIL NUTS — alternative natural source; eating 5+ daily can chronically exceed UL; (5) PREGNANCY/LACTATION — RDA-level safe (60-70 µg/day); high-dose AVOID; (6) YEAST ALLERGY — rare; verify tolerance before use; (7) DRUG INTERACTIONS — chemotherapy (consult oncologist), warfarin theoretical bleeding; (8) NPC vs SELECT history is a teaching example of how preliminary positive findings on secondary endpoints often fail confirmatory rigorous trials; (9) Selenium yeast vs pure selenomethionine — both are effective for repletion; selenium yeast preferred by some for 'whole-food' positioning, but pure selenomethionine has more standardized speciation.